May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Combined Angiostatic and Periocular Chemotherapy Using Combretastatin A4P And Carboplatin in the Treatment of LHBETATAG Transgenic Murine Model of Retinoblastoma
Author Affiliations & Notes
  • T.G. Murray
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL
  • M.E. Jockovich
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL
  • F. Suarez
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL
  • E. Hernandez
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL
  • W. Feuer
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL
  • Footnotes
    Commercial Relationships  T.G. Murray, Oxigene, F; M.E. Jockovich, Oxigene, F; F. Suarez, Oxigene, F; E. Hernandez, Oxigene, F; W. Feuer, None.
  • Footnotes
    Support  Supported by Oxigene, Inc, NIH R01 EY013629, NIH center grant P30 EY014801 and by an unrestricted grant to the University of Miami from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2290. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T.G. Murray, M.E. Jockovich, F. Suarez, E. Hernandez, W. Feuer; Combined Angiostatic and Periocular Chemotherapy Using Combretastatin A4P And Carboplatin in the Treatment of LHBETATAG Transgenic Murine Model of Retinoblastoma . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2290.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate tumor control efficacy and to determine optimal drug delivery scheduling for the combined treatment of murine transgenic retinoblastoma, using Combretastatin A4P (CA4P), an angiostatic agent, and Carboplatin.

Methods: : All experiments in this study were conducted in accordance with ARVO guidelines. A. 10 week–old LHBETATAG mice (six mice per group) were treated with subtherapeutic doses of Carboplatin (62.5 µg/20µl) delivered via six bi–weekly subconjunctival injections to right eyes only; left eyes served as untreated controls. CA4P (1mg/20µl) was delivered one day prior or one day following Carboplatin injections. B. 10 week–old LHBETATAG mice (six mice per group) were treated with 62.5 µg/20µl of Carboplatin delivered via three weekly subconjunctival injections. CA4P (1mg/20µl) was delivered one day prior or one day following Carboplatin injections. Control mice received either drug alone or saline. Eyes were analyzed at 16 weeks of age.

Results: : Histological assessment of tumor volume suggests a dose and drug delivery scheduling dependent tumor response to the combined treatment. Disrupting vessels prior to chemotherapy results in inhibition of tumor control; disrupting vessels following chemotherapy results in an additive, though not statistically significant effect in the control of tumor burden. Functional assays suggest that treatment with CA4P results in vascular closure one day post–delivery and vessel reperfusion one week later. To test the hypothesis that functional vessels are necessary for chemotherapy delivery injections were performed one week intervals. A statistically significant (p<0.05) reduction in tumor burden is detected when weekly injections of carboplatin were performed following vessel closure with CA4P.

Conclusions: : Subconjunctival delivery of CA4P combined with Carboplatin effectively inhibits intraocular tumor burden in the LHBETATAG model of retinoblastoma. Vessel disruption prior to chemotherapy results in inhibition of chemotherapy efficacy. This combined treatment affords the dual benefit of closing intratumoral blood flow while potentially increasing intraocular drug concentration. This treatment modality may represent a novel strategy for the treatment of pediatric retinoblastoma.

Keywords: retinoblastoma • tumors • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×